Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA

Teva Pharmaceutical Industries receivables for the quarter ending June 30, 2024 were $3.766B, a 6.41% increase year-over-year.

  • Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
  • Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
  • Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.

Teva Pharmaceutical Industries Receivables 2010-2024 | TEVA

  • Teva Pharmaceutical Industries receivables for 2023 were $3.408B, a 7.79% decline from 2022.
  • Teva Pharmaceutical Industries receivables for 2022 were $3.696B, a 18.39% decline from 2021.
  • Teva Pharmaceutical Industries receivables for 2021 were $4.529B, a 1.14% decline from 2020.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$13.1B
BridgeBio Pharma (BBIO)$5B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M